Furo[3,2-c]pyrazole derivatives of formula (I) as defined in the description, and pharmaceutically acceptable salts thereof, wherein A is an aryl or heteroaryl ring, &mdash；NHZR5 is at the ortho position to the CONH linker； &mdash；R1 and R2 are the same or different and, independently from each other, represent a hydrogen atom, or an organic residue； R3 is a hydrogen or halogen atom or an organic group； R4 is a hydrogen or halogen atom or an organic group； Z is direct bond, >；C&boxH；O, or &mdash；C(&boxH；O)NH&mdash；； &mdash；R5 is hydrogen or an optionally substituted organic group or isomers, tautomers, carriers, metabolites, prodrugs, and pharmaceutically acceptable salts thereof. A process for their preparation and pharmaceutical compositions comprising them are disclosed； the compounds of the invention may be useful, in therapy, in the treatment of diseases associated with a disregulated protein kinase activity, in particular Aurora kinases activity or IGF-1R activity, like cancer.
